Changes in Hong Kong stocks | Heplatinum Pharmaceutical-B (02142) rose more than 8% in early trading, and the company signed a BD deal of more than 1 billion US dollars with Bristol-Myers Squibb

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose more than 8% in early trading. As of press release, it had risen 6.79% to HK$13.36, with a turnover of HK$25.2071 million.

According to the news, Heplatinum Pharmaceuticals announced that the company and Bristol-Myers Squibb have signed a multi-year global strategic cooperation and licensing agreement to discover and develop a new generation of multi-specific antibodies. According to the agreement, Heplatinum Pharmaceuticals will receive a total down payment of US$90 million. If Bristol-Myers Squibb advances all potential projects, the company will also be eligible for development and commercial milestone payments of up to US$1,035 million and tiered royalties. According to the terms of the agreement, the two sides will cooperate to advance and accelerate the discovery of multi-specific antibodies.

It is worth noting that since 2025, Hebo Pharmaceutical has won three major MNC orders. At the beginning of the year, the company had a major cooperation of up to 4,575 billion yuan, involving the development of multiple targets and projects. The latter also invested 105 million US dollars in equity and established the Beijing Innovation Center to deepen the bond. In June, Platinum Pharmaceuticals and Otsuka Pharmaceutical reached a global strategic cooperation on the BcMaxCD3 bispecific T-cell adapter (HBM7020). According to reports, the total amount of cooperation with MNC has been reached seven times with Platinum Pharmaceuticals, and the total amount of foreign cooperation has exceeded 10 billion US dollars.